Pfizer to File Early NDA for it's Breast Cancer Drug Palbociclib

Encouraging results from mid-trial analysis have prompted an early halt of the clinical trial for palbociclib and plans to apply for approval.

Pfizer Inc. said Friday that the Food and Drug Administration will let the drugmaker apply for approval of its heavily touted experimental breast cancer medicine based on midstage patient testing results.

That means New York-based Pfizer won't have to do bigger, and very expensive, late-stage patient studies to apply for approval of palbociclib, as company executives and investors had hoped.

Having to run those additional studies could have delayed Pfizer's application by up to a couple of years, keeping patients and doctors waiting and ultimately reducing how much money the drug could bring Pfizer before its 20-year patent expires.

Pfizer, the world's second-biggest drugmaker by revenue, said that after discussions with the FDA, the final results of a study called PALOMA-1 will be sufficient for review.

Read the complete report here:

Source: abc News

Related Videos
Related Content
© 2023 MJH Life Sciences
All rights reserved.